Recent 8-K filings for LNTH

• August 6, 2026, 7:45 AM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Lantheus Q2 revenue $388.2M, EPS $1.11; suspends FY2026 guidance due to pending Curium merger

  Worldwide revenue $388.2M, up 2.7% YoY; GAAP EPS $1.11 vs $1.12; adjusted EPS $1.55 vs $1.57.

• August 3, 2026, 9:00 PM ET M&A materiality 0.90 neutral item 1.01item 5.02item 9.01

  Lantheus to be acquired by Curium for $102.50/share plus up to $12.00 in CVRs

  Total consideration up to $114.50/share: $102.50 cash plus CVRs tied to commercial milestones for prostate cancer, neurology, and DEFINITY franchises.

• August 3, 2026, 8:37 AM ET M&A materiality 1.00 positive item 7.01item 8.01item 9.01

  Curium to acquire Lantheus for up to $114.50/share ($8.0B); 38% premium to 60-day VWAP

  Total consideration up to $114.50/share: $102.50 cash at closing plus up to $12.00 in CVRs tied to commercial milestones through 2030.

• May 7, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Lantheus Q1 revenue $377.3M (+1.2% YoY); GAAP EPS $1.80, adjusted EPS $1.46

  Worldwide revenue $377.3M (+1.2%); GAAP diluted EPS $1.80 (+76.5%), adjusted diluted EPS $1.46 (-4.6%).

• May 1, 2026, 7:59 PM ET other material materiality 0.60 neutral item 3.03item 5.03item 5.02item 5.07item 9.01 ◈ Shareholder Votes ×6◈ Governance Changes

  Lantheus shareholders approve board declassification and amended equity plan with 2M additional shares

  Certificate of Amendment filed to declassify Board of Directors over three years; removal with/without cause after declassification.

• February 26, 2026, 6:59 PM ET earnings materiality 0.50 neutral item 2.02item 9.01

  Lantheus Q4 revenue $406.8M, adj EPS $1.67; narrows focus to PET radiodiagnostics

  Worldwide revenue $406.8M (+4% YoY); FY2025 revenue $1.54B; GAAP diluted EPS $0.82 Q4, $3.41 FY.

• November 12, 2025, 6:59 PM ET leadership materiality 0.65 neutral item 5.02

  Lantheus CEO Brian Markison to retire Dec 31, 2025; consulting deal through Mar 31, 2026

  CEO Brian Markison retiring effective Dec 31, 2025; enters consulting agreement from Jan 1 to Mar 31, 2026.

• November 6, 2025, 6:59 PM ET earnings materiality 0.85 neutral item 2.02item 5.02item 7.01item 9.01

  Lantheus Q3 revenue $384M (+1.4% YoY), adj. EPS $1.27; CEO Markison to retire, Heino interim CEO

  GAAP net income $27.8M ($0.41 fully diluted EPS); adjusted EPS $1.27, down 25.3% YoY.

• August 11, 2025, 7:59 PM ET leadership materiality 0.40 neutral item 5.02

  Lantheus CCO Amanda Morgan takes personal leave effective Aug. 8, 2025

  Chief Commercial Officer Amanda Morgan on personal leave starting August 8, 2025.

• August 6, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 7.01item 8.01item 9.01

  Lantheus Q2 rev $378M, adj EPS $1.57; cuts FY25 guidance; FDA NDA acceptance; $400M buyback

  Q2 revenue $378.0M (-4.1% YoY); GAAP EPS $1.12; adjusted EPS $1.57.

• July 22, 2025, 7:59 PM ET M&A materiality 0.75 positive item 2.01item 7.01item 9.01 ◈ M&A Transactions

  Lantheus closes $350M acquisition of Life Molecular Imaging; names Dr. Dinkelborg as Head of R&D

  Completed acquisition of Life Molecular for $350M cash after adjustments, gaining Alzheimer's PET agent Neuraceq.

• May 7, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Lantheus Q1 adj EPS $1.53 (-9.5% YoY); cuts FY25 adj EPS guidance to $6.60-$6.70 from $7.00-$7.20

  Q1 revenue $372.8M (+0.8% YoY); GAAP EPS $1.02 vs $1.87; adj EPS $1.53 vs $1.69.

• May 5, 2025, 7:59 PM ET other material materiality 0.50 neutral item 5.03item 5.07item 9.01 ◈ Governance Changes

  Lantheus stockholders elect four Class I directors and approve board declassification proposal

  All four nominees elected: Mary Anne Heino (54.3M for), Dr. Gérard Ber (57.2M for), Julie Eastland (56.1M for), Samuel Leno (41.5M for).

• April 1, 2025, 7:59 PM ET M&A materiality 0.75 positive item 2.01item 7.01item 9.01 ◈ M&A Transactions

  Lantheus closes $275M acquisition of Evergreen Theragnostics; adds OCTEVY and CDMO capabilities

  Closed acquisition of Evergreen Theragnostics for $275M cash upfront ($250M + $25M milestone achieved pre-close).

• February 26, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Lantheus Q4 revenue $391M (+10.5%); GAAP EPS $(0.17), adj. EPS $1.59; FY25 guide $1.55B-$1.61B

  Q4 revenue $391.1M (+10.5% YoY); PYLARIFY $266M (+15.7%), DEFINITY $86.2M (+17.9%).

• January 30, 2025, 6:59 PM ET leadership materiality 0.45 positive item 5.02item 9.01 ◈ executive_change

  Lantheus appoints Dr. Phuong Khanh Morrow to board, effective Feb 1, 2025

  Dr. Phuong Khanh Morrow appointed independent director effective Feb 1, 2025; board expands to 11.

• January 28, 2025, 6:59 PM ET M&A materiality 0.85 positive item 1.01item 2.02item 7.01item 9.01

  Lantheus to acquire Evergreen Theragnostics for $250M upfront plus up to $752.5M in milestones

  Upfront cash consideration $250M; potential milestone payments up to $752.5M based on OCTEVY and pipeline products.

• January 13, 2025, 6:59 PM ET M&A materiality 0.90 positive item 1.01item 7.01item 9.01

  Lantheus to Acquire Life Molecular Imaging for $350M Upfront with Potential $400M Earnout

  Upfront cash payment of $350M for Life Molecular Imaging, with up to $400M in potential earnout and milestone payments.

• December 23, 2024, 6:59 PM ET debt materiality 0.72 positive item 1.01item 2.03item 9.01

  Lantheus expands revolving credit facility to $750M, extends maturity to Dec 2029

  Revolving line increased from $350M to $750M; can request another $350M.

• December 19, 2024, 6:59 PM ET leadership materiality 0.50 neutral item 7.01

  Lantheus CMO Jeff Humphrey to depart Jan 3, 2025; search underway for replacement

  Jeff Humphrey, MD, resigns as Chief Medical Officer; last day January 3, 2025.

• November 20, 2024, 6:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Lantheus authorizes $250M share repurchase program over next 12 months

  Board authorized up to $250M in common stock repurchases within one year.

• November 6, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Lantheus Q3 revenue up 18.4% to $378.7M; adjusted EPS $1.70 beats prior year

  GAAP net income $131.1M ($1.79 diluted EPS) vs $132.0M ($1.88) in Q3 2023.

• September 25, 2024, 7:59 PM ET other material materiality 0.65 neutral item 7.01

  Lantheus to release SPLASH trial data in Oct 2024 after 75% OS events reached

  Expects to release Phase 3 SPLASH data in October 2024 for 177Lu-PNT2002 in PSMA-expressing mCRPC.

• September 5, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02item 9.01 ◈ executive_change

  Lantheus appoints Julie Eastland to Board of Directors, effective Sept 3, 2024

  Board size increased to ten directors; Eastland is a Class I director and Audit Committee member.

• July 31, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Lantheus Q2 revenue up 22.5% to $394.1M, adjusted EPS $1.80; lowers FY 2024 adjusted EPS guidance to $6.60-$6.70

  Revenue $394.1M (+22.5% YoY), driven by PYLARIFY sales $273.3M (+29.8%) and DEFINITY $78.1M (+10.7%).

• June 27, 2024, 7:59 PM ET M&A materiality 0.68 positive item 7.01item 9.01

  Lantheus acquires global rights to Life Molecular's GRPR-targeting radiotheranostic pair for $35M upfront

  Upfront payment $35M plus regulatory milestone payments and royalties.

• June 24, 2024, 7:59 PM ET leadership materiality 0.45 neutral item 5.02 ◈ executive_change ×2

  Lantheus appoints Kimberly Brown as Chief Accounting Officer effective July 1, 2024

  Brown joins from Repligen (VP Controller); Andrea Sabens transitions to new role as of August 1.

• May 15, 2024, 7:59 PM ET leadership materiality 0.40 neutral item 5.02item 9.01 ◈ executive_change

  Lantheus appoints new CMO and CSO; Humphrey and Provost roles change May 28

  Jeffrey S. Humphrey, MD appointed Chief Medical Officer; Jean-Claude Provost, MD named Chief Science Officer, both effective May 28, 2024.

• May 2, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Lantheus Q1 revenue $370M (+23% YoY), EPS $1.87; raises FY2024 guidance

  Q1 revenue $370M (+23% YoY); PYLARIFY sales $258.9M (+32.4%), DEFINITY $76.6M (+11.2%)

• April 29, 2024, 7:59 PM ET other material materiality 0.30 neutral item 5.02item 5.07item 9.01 ◈ Shareholder Votes ×4

  Lantheus shareholders approve 4M share equity plan increase; re-elect directors

  Stockholders approved amendment increasing share reserve under 2015 Equity Incentive Plan by 4,000,000 to 14,930,277.

• February 22, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Lantheus Q4 2023 rev $354M (+34.5%), adj EPS $1.75; FY2024 guidance raised

  Q4 2023 revenue $354M (+34.5% YoY), including $15M RELISTOR milestone; FY2023 revenue $1.3B (+38.6% YoY).

• January 26, 2024, 6:59 PM ET litigation materiality 0.60 neutral item 7.01

  Lantheus confirms patent infringement lawsuit by Novartis over generic Lutetium Lu 177 Dotatate ANDA

  Lawsuit filed by Advanced Accelerator Applications (Novartis entities) in U.S. District Court for Delaware against Lantheus and its subsidiary.

• January 23, 2024, 6:59 PM ET leadership materiality 0.80 positive item 5.02item 9.01 ◈ executive_change ×5

  Lantheus CEO Heino retires March 1; Markison named CEO; FY23 revenue $1.295-1.297B, up 38-39%

  Mary Anne Heino to retire as CEO effective March 1, 2024; becomes Chair of the Board.

• January 9, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Lantheus pre-announces FY2023 revenue ~$1.296B, beating guidance; PYLARIFY up 62%

  Worldwide revenue expected $1.295-1.297B, up 38-39% YoY, above prior guidance of $1.255-1.270B.

• November 2, 2023, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Lantheus Q3 revenue $319.9M (+33.7% YoY); raises FY2023 guidance

  Revenue $319.9M, +33.7% YoY; GAAP net income $132.0M vs $61.2M YoY.

• August 28, 2023, 7:59 PM ET other material materiality 0.30 neutral item 5.02

  Lantheus increases CFO and CBO compensation; base salary to $650K and $575K

  CFO Robert Marshall salary raised to $650K, bonus target 75% of salary, LTIP target $3M.

• August 18, 2023, 7:59 PM ET other material materiality 0.60 negative item 8.01

  Lantheus discontinues AZEDRA production; winds down Somerset, NJ site

  Progenics Pharmaceuticals subsidiary to stop manufacturing and promoting AZEDRA.

• August 3, 2023, 7:59 PM ET other material materiality 0.85 positive item 2.02item 7.01item 8.01item 9.01 ◈ Earnings Releases

  Lantheus Q2 revenue up 44% to $322M; sells RELISTOR royalties for ~$98M upfront, raises FY guidance

  Q2 revenue $321.7M (+43.8% YoY); GAAP net income $94.1M ($1.33 diluted EPS); adjusted EPS $1.54

• May 4, 2023, 7:59 PM ET other material materiality 0.50 neutral item 1.01item 2.03 ◈ Material Agreements

  Lantheus expands Bedford lease by 41,655 sq ft; total rent ~$83.4M over 15 yrs 4 mo

  Lease amendment adds 41,655 rentable sq ft in north building for office/lab use; term 15 years 4 months.

• May 4, 2023, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Lantheus Q1 revenue $300.8M (+44% YoY); adjusted EPS $1.47; raises full-year guidance

  Revenue $300.8M, +44% YoY; GAAP net loss $2.8M vs net income $43M prior year.

• May 1, 2023, 7:59 PM ET other materiality 0.30 neutral item 5.02item 5.07item 9.01 ◈ Shareholder Votes ×4

  Lantheus shareholders approve 2023 ESPP and elect directors at annual meeting

  Approved 2023 Employee Stock Purchase Plan with 57,911,119.90 votes for (99.85% of votes cast).

• March 20, 2023, 7:59 PM ET leadership materiality 0.50 neutral item 5.02item 9.01 ◈ executive_change

  Lantheus promotes Paul Blanchfield to President, Dan Niedzwiecki to CAO

  Paul Blanchfield appointed President effective March 20, 2023; CEO Mary Anne Heino remains CEO.

• March 17, 2023, 7:59 PM ET leadership materiality 0.40 positive item 5.02item 9.01 ◈ executive_change

  Paul Blanchfield promoted to Lantheus President effective March 20, 2023; Dan Niedzwiecki elevated to CAO

  Blanchfield, previously COO, will oversee Commercial, Technical Operations, Manufacturing, Quality, and Medical.

• February 23, 2023, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Lantheus Q4 revenue up 103% to $263.2M; FY2022 revenue $935.1M; guides FY2023 revenue $1.14-1.16B

  Q4 2022 revenue $263.2M (+103.1% YoY); FY2022 revenue $935.1M (+119.9% YoY).

• February 6, 2023, 6:59 PM ET M&A materiality 0.65 positive item 7.01item 9.01

  Lantheus acquires Cerveau Technologies, adding Alzheimer's Tau PET imaging agent MK-6240

  Acquired Cerveau Technologies, gaining MK-6240, an F18-labeled PET imaging agent targeting Tau tangles in Alzheimer's disease.

• January 11, 2023, 6:59 PM ET other materiality 0.30 neutral item 7.01item 9.01

  Lantheus presents at J.P. Morgan Healthcare Conference; no specific material updates disclosed in filing

  Filed presentation slides for 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023.

• December 28, 2022, 6:59 PM ET other materiality 0.20 neutral item 5.03item 9.01 ◈ Governance Changes

  Lantheus amends bylaws: majority voting, universal proxy rules, DGCL updates

  Board adopted Amended and Restated Bylaws effective December 27, 2022.

• December 20, 2022, 6:59 PM ET M&A materiality 0.90 positive item 2.01item 8.01item 9.01

  Lantheus closes strategic collaboration & license agreements with POINT Biopharma for PNT-2002 and PNT-2003

  Paid $250M upfront for PNT-2002 (prostate cancer therapy); $10M upfront for PNT-2003 (neuroendocrine tumor therapy).

• December 8, 2022, 6:59 PM ET debt materiality 0.65 neutral item 1.01item 2.03item 3.02item 8.01item 9.01 ◈ Debt Financings◈ Material Agreements

  Lantheus closes $575M 2.625% convertible notes offering, repurchases $75M stock

  Issued $575M aggregate principal of 2.625% Convertible Senior Notes due 2027, including $75M overallotment.

• December 6, 2022, 6:59 PM ET debt materiality 0.65 neutral item 8.01item 9.01

  Lantheus prices $500M convertible senior notes at 2.625% due 2027; net proceeds ~$485M for buybacks, corporate purposes

  Offers $500M in 2.625% convertible senior notes due Dec 15, 2027; initial purchasers may buy up to $75M more.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 1.00 · Median 0.65 · Most common event earnings

21 positive 2 negative 27 neutral

source · LNTH on sec.gov